In the aftermath of COVID-19, France faced an uncomfortable diagnosis: despite hosting Sanofi — one of the world’s largest pharmaceutical companies — it could not rapidly manufacture vaccines on its own soil. API ingredients came from Indian and Chinese suppliers. Fill-and-finish capacity was shared across European partners. Domestic bioreactor capacity was insufficient for emergency scale-up. France 2030’s bioproduction initiative exists to make that vulnerability structurally impossible to repeat.

The €800 million ProFIL program (Programme France Infrastructure Laboratoire) is the largest dedicated bioproduction investment in French history. Eight pilot manufacturing sites, selected through competitive call in 2022-2023, will give France end-to-end domestic capability across the full spectrum of biological medicines: recombinant proteins, monoclonal antibodies, mRNA vaccines, viral vectors for gene therapy, cell therapies, and fermentation-derived small molecules.

The ProFIL Architecture

ProFIL is not a single facility. It is a coordinated national network — a deliberate echo of France’s successful nuclear infrastructure model, where distributed capacity serves both commercial and strategic purposes.

Site 1: Sanofi Vitry-sur-Seine — mRNA Manufacturing Hub

The flagship site. Sanofi is investing over €1 billion in its Vitry-sur-Seine campus south of Paris to create France’s first dedicated mRNA Center of Excellence. The facility, operational for clinical-scale manufacturing in 2025, will combine mRNA synthesis, lipid nanoparticle formulation, fill-and-finish, and analytical testing under one roof. France 2030 contributed €200 million from the ProFIL envelope, with Sanofi funding the remainder. Peak capacity: enough mRNA vaccine doses to cover the entire French population within 90 days of a pandemic declaration — the explicit strategic objective.

Site 2: CEA-Tech Grenoble — Gene Therapy Vectors

The Commissariat à l’Énergie Atomique’s Grenoble biotechnology division received €85 million from ProFIL to build a GMP-grade viral vector manufacturing facility. Adeno-associated viruses (AAVs) and lentiviral vectors are the delivery vehicles for gene therapies — the fastest-growing segment of the biopharmaceutical market. France lacked any commercial-scale domestic vector manufacturing capacity prior to this investment. The facility targets 10,000L annual bioreactor capacity and serves as a shared-use manufacturing platform for French gene therapy startups.

Site 3: Evotec Saint-Eloi, Toulouse — Microbial Fermentation

Evotec, the German contract research and manufacturing organization, selected Toulouse for its French bioproduction expansion after a competitive process partially incentivized by France 2030. The Saint-Eloi facility focuses on microbial fermentation for complex APIs — a capability increasingly critical as antibiotics, antifungals, and biosimilar insulins shift back toward European production. France 2030 contributed €60 million; Evotec invested €120 million.

Site 4: Poietis, Bordeaux — Bioprinting for Cell Therapy

The most technologically radical site in the ProFIL network. Poietis, a Bordeaux-based bioprinting company founded in 2014, received €40 million from France 2030 to develop automated cell therapy manufacturing using its proprietary laser-assisted bioprinting technology. The target application: producing standardized CAR-T cell therapies at scale, addressing the primary bottleneck in commercializing personalized cancer immunotherapies.

Sites 5-8: Additional Nodes (in planning/construction)

Sites five through eight are being developed in partnership with CHU Paris-Saclay (cell therapy for rare diseases), Servier (complex biologics), LFB Biomedicaments (plasma-derived medicines, expansion of Les Ulis facility), and Transgene (oncolytic virotherapy manufacturing). Total public investment across these four sites: approximately €300 million.

EU IPCEI Health: The European Multiplier

France secured a leading role in the European IPCEI Health project announced in 2023. IPCEI (Important Projects of Common European Interest) is the EU mechanism that allows member states to provide state aid above normal limits for projects with pan-European strategic significance.

The Health IPCEI spans 13 EU member states and covers the full value chain from research through manufacturing. French participation focuses on three workstreams:

Workstream A: mRNA Platform Infrastructure — Sanofi’s Vitry site is designated as a European manufacturing node under IPCEI Health, enabling it to receive both French state aid (France 2030) and EU co-financing. Total public support under this workstream: approximately €500 million across all participating countries, with France capturing the largest single-country share.

Workstream B: Biotherapies Production Chain — Covers raw material sourcing (bioreactor equipment, culture media, lipid nanoparticle components) where France identified critical dependencies on non-European suppliers. At least three French companies in the bioproduction supply chain received IPCEI Health designation, unlocking higher state-aid intensity.

Workstream C: AI-Accelerated Drug Development — Connects France’s Health Data Hub to IPCEI Health’s data sharing infrastructure, enabling French AI health companies to access European patient data cohorts while contributing to a shared European pharma AI commons.

The Biotherapy Revolution: What France Is Actually Producing

Biotherapies are medicines derived from biological sources — proteins, antibodies, nucleic acids, cells — as opposed to chemically synthesized small molecules. They currently represent 30% of global pharmaceutical revenues and are growing at 8% annually. By 2030, biotherapies are projected to account for 50% of new drug approvals.

France’s historical strength has been in chemical synthesis, particularly at Sanofi’s large Quimper, Tours, and Mourenx manufacturing sites. The France 2030 bioproduction pivot is a deliberate industrial strategy shift toward the higher-value biological medicines segment.

The specific therapeutic categories prioritized under ProFIL map directly to France’s existing research strengths:

Monoclonal antibodies: France has five major academic research centers with world-class antibody engineering programs (Institut Pasteur, CNRS, INSERM at Montpellier, Paris-Saclay, Bordeaux). ProFIL infrastructure converts that research advantage into manufacturing capacity.

mRNA therapeutics: Beyond COVID vaccines, mRNA is advancing in oncology (personalized cancer vaccines), rare diseases (enzyme replacement), and infectious disease. Sanofi’s mRNA Center of Excellence positions France at the commercial vanguard of this technology transition.

Cell therapies: CAR-T cells and TIL (tumor-infiltrating lymphocyte) therapies represent the highest-value, most complex segment of biotherapeutics. France’s France 2030 investment in automated manufacturing (Poietis) and shared GMP infrastructure (CEA-Tech) targets the primary commercial bottleneck in this market.

Bioproduction supply chain: Raw materials — culture media, growth factors, bioreactor consumables — are a chokepoint that COVID exposed catastrophically. France 2030 has committed €120 million specifically to French suppliers of bioproduction consumables, including Novatek International (bioreactor automation) and Sartorius Stedim Biotech (French subsidiary expansion).

Performance Metrics and Timeline

As of Q1 2026:

• ProFIL Commitment rate: 87% of €800M envelope committed
• Sites in active construction: 5 of 8
• Sites operational for clinical manufacturing: 2 (Sanofi Vitry Phase 1, LFB Les Ulis expansion)
• Jobs created or sustained: approximately 2,400 direct manufacturing positions
• Private co-investment mobilized: €1.8 billion (2.25:1 ratio vs public funding)
• Target year for all 8 sites operational: 2027

The strategic gap: ProFIL is on track for infrastructure, but France’s bioproduction workforce pipeline remains a concern. The Institut du Biomédicament (IDB), a France 2030-funded training initiative, was established in 2023 to train 5,000 bioproduction technicians and engineers by 2027. As of 2026, enrollment is running at 60% of target, requiring acceleration.

Comparison: France vs Germany vs Belgium

Germany has invested approximately €1 billion in bioproduction through its BMBF (Federal Ministry of Education and Research) programs, anchored by BioNTech’s mRNA manufacturing expansion in Marburg (250 million doses annual capacity). Germany has first-mover advantage in mRNA manufacturing from the COVID vaccine experience.

Belgium operates arguably Europe’s most mature bioproduction cluster, anchored by Janssen (J&J) in Beerse, UCB in Braine-l’Alleud, and GSK Biologicals in Wavre. Belgium produces approximately 1 in 5 vaccines used globally — an extraordinary concentration that France aspires to challenge.

France’s ProFIL program is the most ambitious new bioproduction investment in Europe by a country starting without an established cluster. The Vitry mRNA hub, when fully operational, will position France alongside Germany as one of two sovereign mRNA manufacturing powers in Europe.

Related: Sanofi France 2030 investments | Health Data Hub | Pandemic Preparedness Program | Health Funding Tracker